home / stock / apto / apto news

APTO News and Press, Aptose Biosciences Inc. From 01/02/19

Stock Information
Company Name: Aptose Biosciences Inc.
Stock Symbol: APTO
Market: NASDAQ
Website: aptose.com
Menu
APTO APTO Quote APTO Short APTO News APTO Articles APTO Message Board
Get APTO Alerts

News, Short Squeeze, Breakout and More Instantly...
APTO - Factors of Influence in 2019, Key Indicators and Opportunity within The TJX Companies, Nasdaq, Werner Enterprises, Global Ship Lease, Domo, and Aptose Biosciences - New Research Emphasizes Economic Growth

NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The TJX Companies, Inc. (NYSE:TJX), Nasdaq, Inc. (NASDAQ:NDAQ), Werner En...
APTO - Aptose Biosciences to Present at Biotech Showcase(TM) 2019 Conference

SAN DIEGO and TORONTO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President...

APTO - OHSU and Aptose Present New CG-806 Preclinical Data at ASH 60th Annual Meeting

PORTLAND, Ore. and SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Oregon Health & Science University (OHSU) and Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today announced the presentation of preclinical data demonstrating that CG-806, a first-in-class pan-FLT3/pan-BTK inhibitor, exh...

APTO - Aptose Presents New Preclinical Data on CG-806 PAN-FLT3/PAN-BTK Inhibitor at ASH 60th Annual Meeting

SAN DIEGO and TORONTO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today announced the presentation of preclinical data from research led by The University of Texas MD Anderson Cancer Center exploring the mechanism by which CG-806, a highly potent pan-...
APTO - Aptose to Participate in Upcoming Investor Conferences, Host Key Opinion Leader Event, and Present Data at the Upcoming ASH Meeting

SAN DIEGO and TORONTO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today an...

APTO - Aptose Biosciences Inc. (APTO) CEO William Rice on Q3 2018 Results - Earnings Call Transcript

Aptose Biosciences Inc (APTO) Q3 2018 Earnings Conference Call November 07, 2018, 08:00 PM ET Executives Susan Pietropaolo - SMP Communications William Rice - Chairman, President, and CEO Gregory Chow - SVP and CFO Analysts Jotin Marango - ROTH Capital Joe Pantginis - HC ...

APTO - Aptose Biosciences reports Q3 results

Aptose Biosciences (NASDAQ: APTO ): Q3 GAAP EPS of -$0.16. More news on: Aptose Biosciences Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

APTO - Aptose Reports Results for the Third Quarter Ended September 30, 2018

Conference call is scheduled for tomorrow, Wednesday, November 7 th at 8:00 AM ET SAN DIEGO and TORONTO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing high...

APTO - Aptose to Present New CG-806 Data at the 2018 ASH Annual Meeting

SAN DIEGO and TORONTO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announc...

APTO - Aptose Biosciences and CrystalGenomics announce issuance of European patent for CG-806

Aptose Biosciences (NASDAQ: APTO ) announces that the European Patent Office has issued European Patent No. EP2940014B1 for CG-806, a highly potent oral small molecule being developed for acute myeloid leukemia (AML), B cell and other hematologic malignancies. More news on: Aptose B...
Previous 10 Next 10